Searchable abstracts of presentations at key conferences in endocrinology

ea0011p735 | Steroids | ECE2006

Prevalence of classical forms of 21-hydroxylase deficiency in Western Siberia according to the results of neonatal screening of congenital adrenal hyperplasia

Suplotova LA , Hramova EB , Makarova OB , Yuzakova NU , Barcova TV

The purpose: to study prevalence of classical forms of 21-hydroxylasae deficiency according to the results of neonatal screening on a congenital adrenal hyperplasia (CAH) in Tyumen, Russia.The analysis of neonatal screening on CAH results in Tyumen for the period of 2003–2004. For the period under research 20011 newborn have been tested on the 17-OHP level. Measurement of 17-hydroxyprogesterone in blood samples was done in the central laboratory by ...

ea0062p17 | Poster Presentations | EU2019

Self-diagnosis of De la Chapelle syndrome

Ahmad Sajjad , Ravindran Ravikumar , Lansdown Andrew

Case history: A 30 years old male Caucasian had his saliva tested on a self-funded commercial DNA testing to identify his ancestral roots. The markers for Y chromosome were found to be absent and further evaluation revealed him to have 46 XX karyotype.This was consistent with the diagnosis of De la Chapelle syndrome or XX male syndrome. Fluorescence in situ hybridization (FISH) studies confirmed the presence of SRY (sex determining region Y) gene which was responsible...

ea0089c3 | Clinical – Chemo/SSA/Biologics | NANETS2022

Real World Analysis of Long-Acting Somatostatin Analog (LA-SSA) Treatment and Dose Escalation Among Patients with Neuroendocrine Tumors (NET)

Clarke, MD, MS Callisia N. , Cockrum, BSci, PharmD, RPh Paul , Beveridge, MSc, PhD Thomas J.R. , Jerry, MS Michelle , McMorrow, BS Donna , Thu Tran, PharmD Anh , Phan, MD Alexandria T.

Background: LA-SSA therapy, including octreotide long-acting release (LAR) and lanreotide depot (LAN), is recommended as first-line therapy for treatment of unresectable or metastatic NETs. Understanding treatment sequencing and dosing patterns of LA-SSAs is essential for clinical decision-making to provide value-based management of NET for both the patients and healthcare system. This study describes treatment patterns of LA-SSA therapy among privately insured patients with N...

ea0070aep596 | Pituitary and Neuroendocrinology | ECE2020

Efficacy and safety of long-acting pasireotide (LA-PAS) in patients with uncontrolled acromegaly: Results from the prospective cohort of european observational acronis study

Pivonello Rosario , Tabarin Antoine , Colao Annamaria , Kaltsas Gregory , Gonzalez-Molero Inmaculada , Neggers Sebastian , Venegas Moreno Eva , Kocjan Tomaz , Karges Wolfram , Krzyzanowska-Mittermayer Katarzyna , Heck Ansgar , Eden Engstrom Britt , Marques Ruben , O’Brien Eamonn , Manne Shobha , Vincenzi Beatrice , Schöfl Christof

Introduction: Results of the first European real-world evidence from retrospective cohort of ACRONIS study previously confirmed the efficacy and tolerability of LA-PAS in heavily pre-treated, uncontrolled acromegaly patients. Here, we report results of the second interim analysis reflecting the prospective cohort.Methods: Patients who were treated with LA-PAS for ≥6 months were included in this analysis. The primary objective was to document treatm...

ea0029p1134 | Neuroendocrinology | ICEECE2012

Epidemiology, clinical behaviour and prognostic factors of gastroenteropancreatic neuroendocrine tumours in Castilla-La Mancha (Spain) from 1995 to 2010

Marco A. , Vicente A. , Lohuibi L. , Alramadan M. , Aguirre M. , Gomez I. , Herranz S. , Roa C.

Neuroendocrine gastroenteropancreatic tumours (GEP–NETs) are considered rare malignancies that are characterized by their ability to produce a great variety of peptides that may cause characteristic hormonal syndromes. In this study, we examined the epidemiology, clinical behaviour and prognostic factors of GEP–NETs identified in Castilla La Mancha (Spain) from 1995–2010.Patients and methods: Two hundred and sixteen patients with GEP–...

ea0056p1144 | Thyroid cancer | ECE2018

Changing treatment trends with radioiodine in thyroid carcinoma at the beginning of 21st century in Castilla-La Mancha (Spain)

Delgado Manuel , Sastre Julia , Quiroga Ivan , Gonzalez Javier , Torres Belvis , Aznar Silvia , Alvarez Visitacion , Herranz Sandra , Moreno Jesus , Gomez Paz

Background and objective: The incidence of differentiated thyroid carcinoma (DTC) is increasing worldwide. Radioiodine (RAI) ablation is one of the main elements in the therapy of DTC after surgical removal of the gland. This study aims to compare the use of I131 in a Spanish Cohort of DTC before and after the American Thyroid Association (ATA) 2009 guidelines.Patients and methods: The Cadit-CAM study was designed to evaluate retrospectively characterist...

ea0037ep737 | Pituitary: clinical | ECE2015

Clinical features of pituitary adenomas in elderly patients in Castilla La Mancha (Spain) compared with younger age group; a retrospective multicentre study

Vicente Almudena , Val Florentino Del , Cortes Claudia , Lamas Cristina , Aguirre Miguel , Silva Julia , Alramadan Moubarak , Quiroga Ivan

Background: Pituitary adenomas (PAs) in the elderly, defined as people older than 65 years, represent less than 10% of all PAs. Because of increasing life expectancy and improving health care, diagnosis PAs in this age group is increasing with time. Age-related changes and associated diseases may significantly modify the clinical presentation in these patients, delaying the diagnosis of PAs.Objective: To analyse the clinical features of PAs in elderly pa...

ea0081oc4.6 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

ACROBAT advance: once daily, oral paltusotine treatment maintained long-term igf-1 at levels previously achieved with injectable long-acting somatostatin receptor ligands (LA-SRLs)

Gadelha Monica R , Randeva Harpal , Gordon Murray B , Mezosi Emese , Doknic Mirjana , Toth Miklos , Boguszewski Cesar L , Nichols Melissa , Jochelson Theresa , Henley Scott , Patel Meenal , Mendez Debbie Koh , Ferrara-Cook Christine , Krasner Alan , Casagrande Alessandra , Struthers R Scott

Paltusotine is a once-daily, oral, nonpeptide somatostatin receptor type 2 (SST2) specific agonist, in development for the treatment of acromegaly and neuroendocrine tumors. We report interim results from ACROBAT Advance (NCT04261712), an ongoing, multicenter, open-label, long-term extension study of paltusotine in subjects with acromegaly who previously completed either Phase 2 study ACROBAT Edge (NCT03789656) or Evolve (NCT03792555). ACROBAT Edge enrolled 47 subjects with el...

ea0056p432 | Diabetes complications | ECE2018

Association of adverse pregnancy outcomes with glycemic cut-offs stated by the IADPSG, POGS and WHO diagnostic criteria for gestational diabetes mellitus in De La Salle University Medical Center (DLSUMC), Cavite, Philippines from January 2012 to December 2015

Francisco Danica , Andag-Silva Aimee

Objectives: To determine the association between adverse pregnancy outcomes with each of the 75 g OGTT cut-off values prescribed by the World Health Organization (WHO), Philippine Obstetrical and Gynecological Society (POGS), and the International Association of Diabetes in Pregnancy Study group (IASDPG) criteria to help define more appropriate glycemic cut-off levels for Filipinas.Methodology: Retrospective Cohort study of pregnancy deliveries in De La ...

ea0021se1.5 | (1) | SFEBES2009

La Mujer Barbuda by Ribera, 1631: a clinical conundrum

Tunbridge M

The picture showing a markedly virilised central figure with an infant at the breast and a shadowy figure in the background was painted in 1631 by Jose Ribera, a Spaniard living in Naples. It was commissioned by Ribera’s patron, the Duke of Alcela. The painting is of a real named person. The provenance of the painting is well known and through the Duke’s family inheritance it returned to Spain and is to be seen in the Muse Fondacion Duque de Lerma in Toledo. It can a...